News from Holden


Study suggests new approach to treating kids with relapsed cancer.

The study’s findings may provide insight on new approaches or combination therapies to improve other forms of chemotherapy and limit side effects.


Neuroendocrine tumor program earns high European distinction.

The European Neuroendocrine Tumor Center of Excellence designation demonstrates Holden’s full commitment to neuroendocrine tumor care and prevention.